Catherine Angénieux1,2,3,4, Arnaud Dupuis1,2,3,4, Christian Gachet1,2,3,4, Henri de la Salle1,2,3,4, Blandine Maître1,2,3,4. 1. UMR_S1255, INSERM, Strasbourg, France. 2. Etablissement Français du Sang-Grand Est, Strasbourg, France. 3. Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France. 4. Université de Strasbourg, Strasbourg, France.
Abstract
BACKGROUND: Accurate identification of the proportion of young platelets is important to distinguish peripheral thrombocytopenia from a deficit in platelet production. Young platelets are defined by their higher RNA content and are often assessed as thiazole orange bright (TObright ) by flow cytometry. In clinical practice, their proportion is estimated by automatic blood counter according to their greater RNA content, which identifies a so-called immature platelet fraction (IPF). However, the detected IPFs are not strictly identical to the young TObright platelet population observed by flow cytometry. OBJECTIVES: The aim of this study was to assess the reliability of HLA I/major histocompatibility I (MHC I) cell surface expression as a marker of young platelets. METHODS: The HLA I/MHC I expression was evaluated by flow cytometry after costaining blood with TO and antibodies directed against HLA I/MHC I molecules. RESULTS: We found that platelets with a higher expression of plasma membrane-localized MHC I molecules displayed an increased TO staining and a higher content in ribosomal P-antigen. Transfusion experiments in mice showed that the number of MHC I molecules expressed on the cell surface of young murine platelets decreased during platelet aging, reaching basal levels within 24 h. Finally, we demonstrated that for patients with thrombocytopenias, the identification of young platelets is better assessed by the flow cytometric determination of the level of HLA I expression than by TO staining or the use of hematological blood counter. CONCLUSION: Overall, our results highlight the relevance of MHC I/HLA I expression as a valuable parameter to identify young platelets.
BACKGROUND: Accurate identification of the proportion of young platelets is important to distinguish peripheral thrombocytopenia from a deficit in platelet production. Young platelets are defined by their higher RNA content and are often assessed as thiazole orange bright (TObright ) by flow cytometry. In clinical practice, their proportion is estimated by automatic blood counter according to their greater RNA content, which identifies a so-called immature platelet fraction (IPF). However, the detected IPFs are not strictly identical to the young TObright platelet population observed by flow cytometry. OBJECTIVES: The aim of this study was to assess the reliability of HLA I/major histocompatibility I (MHC I) cell surface expression as a marker of young platelets. METHODS: The HLA I/MHC I expression was evaluated by flow cytometry after costaining blood with TO and antibodies directed against HLA I/MHC I molecules. RESULTS: We found that platelets with a higher expression of plasma membrane-localized MHC I molecules displayed an increased TO staining and a higher content in ribosomal P-antigen. Transfusion experiments in mice showed that the number of MHC I molecules expressed on the cell surface of young murine platelets decreased during platelet aging, reaching basal levels within 24 h. Finally, we demonstrated that for patients with thrombocytopenias, the identification of young platelets is better assessed by the flow cytometric determination of the level of HLA I expression than by TO staining or the use of hematological blood counter. CONCLUSION: Overall, our results highlight the relevance of MHC I/HLA I expression as a valuable parameter to identify young platelets.
Authors: Noemí Muñoz-García; María Jara-Acevedo; Carolina Caldas; Paloma Bárcena; Antonio López; Noemí Puig; Miguel Alcoceba; Paula Fernández; Neus Villamor; Juan A Flores-Montero; Karoll Gómez; María Angelina Lemes; Jose Carlos Hernández; Iván Álvarez-Twose; Jose Luis Guerra; Marcos González; Alberto Orfao; Julia Almeida Journal: Cancers (Basel) Date: 2020-11-25 Impact factor: 6.639
Authors: Alicia Veninga; Stefan Handtke; Konstanze Aurich; Bibian M E Tullemans; Sanne L N Brouns; Silas L Schwarz; Floor C J I Heubel-Moenen; Andreas Greinacher; Johan W M Heemskerk; Paola E J van der Meijden; Thomas Thiele Journal: Blood Adv Date: 2022-07-26
Authors: Samuel Kemble; Amanda Dalby; Gillian C Lowe; Phillip L R Nicolson; Steve P Watson; Yotis Senis; Steven G Thomas; Paul Harrison Journal: Blood Adv Date: 2022-05-10